Helicon CEO Peter Abrahamson On Exploiting Niche Markets In China: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
Perth, Australia-based Helicon was established in 2003 to identify and exploit niche market opportunities in the specialty pharmaceutical and health care markets of China and North Asia. The company has licensed exclusive marketing rights for four products: Volplex, Collatamp, MedWrap with Microban and Recell. PharmAsia News' Australian bureau recently sat down with Helicon CEO Peter Abrahamson to discuss the company's business strategy in China.